Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00661609 · OUTCOME

Progression Free Survival (PFS)

A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer · Source last updated 2011-01-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Weeks
Interval / dispersion
Full Range
Time frame
Time from the first administration of study drug to disease progression or death (maximum treatment period of 309 days (44 weeks)

What was measured

Time in weeks from date of first study drug administration to the date of progressive disease according to the RECIST guidelines (Response evaluation in solid tumors, version 1.0), or death due to any cause.

Analysis population: Of the 41 participants who received at least one dose of study medication, only 39 were evaluable for response by RECIST (excludes 2 patients who had baseline scans performed more than 28 days before dosing).

Groups in this outcome

AZD4877

AZD4877 25 mg (Intravenous (IV), 25mg weekly)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
AZD487739

Reported measurements

Source class 1
Values in Weeks · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
AZD48777.3Not reported044Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0
        upper Limit
        44
        value
        7.3
denoms
  1. counts
    1. group Id
      OG000
      value
      39
    units
    Participants
description
Time in weeks from date of first study drug administration to the date of progressive disease according to the RECIST guidelines (Response evaluation in solid tumors, version 1.0), or death due to any cause.
dispersion Type
Full Range
groups
  1. description
    AZD4877 25 mg (Intravenous (IV), 25mg weekly)
    id
    OG000
    title
    AZD4877
param Type
MEDIAN
population Description
Of the 41 participants who received at least one dose of study medication, only 39 were evaluable for response by RECIST (excludes 2 patients who had baseline scans performed more than 28 days before dosing).
reporting Status
POSTED
time Frame
Time from the first administration of study drug to disease progression or death (maximum treatment period of 309 days (44 weeks)
title
Progression Free Survival (PFS)
type
SECONDARY
unit Of Measure
Weeks

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice